key: cord-274331-0i2opmcn
authors: Wang, Catherine J.; Truong, Allison K.
title: COVID‐19 infection on IL‐23 inhibition
date: 2020-07-14
journal: Dermatol Ther
DOI: 10.1111/dth.13893
sha: 
doc_id: 274331
cord_uid: 0i2opmcn

nan

test was negative, and his chest x-ray was normal. Given mild symptoms, the patient was discharged. The next day, the patient returned to the ED with new onset hemoptysis. Computed tomography (CT) chest demonstrated bilateral ground glass opacities and his SARS-CoV-2 polymerase chain reaction (PCR) test was positive. The patient's hospital course was mild, and he was treated symptomatically with nebulizers, benzonatate, and guaifenesin. The patient was discharged 1 week later on home quarantine. Two weeks later, he recovered completely. Per the recommended risankizumab dosing schedule (every 12 weeks after initial loading doses at week zero and four), the patient received his next dose in April with no complications. The patient in this manuscript has given informed consent to publication of his case details.

Risankizumab is a monoclonal antibody that inhibits the p19 subunit of IL-23 1 Another question is when biologics with long half-lives should be restarted. In our case, the patient recovered from COVID-19 before his next scheduled risankizumab dose. However, more data needs to be obtained about biologics in COVID-19 patients, in particular whether or not biologic dosage timeline should be adjusted based on resolution of infection. A database to collect information on COVID-19 patients on biologic therapy and their outcomes would be instrumental to guide clinicians on best practices for now and in future pandemics.

In conclusion, this case illustrates that IL-23 inhibition via biologic therapy in COVID-19 may not correlate with severe respiratory disease. However, the decision to continue biologic treatment should be a shared process between physician and patient on a case-by-case basis.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebocontrolled and ustekinumab-controlled phase 3 trials

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies

TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor